ClinicalTrials.gg
CompletedNCT00284141Updated Dec 10, 2012Results posted

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

A Phase 2 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in Pulmonary Diseases and Neoplasms, Lung, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-10.

Primary conditionLung NeoplasmsRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lung Neoplasms
Why
  1. The study's listed conditions name Lung Neoplasms, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies in Lung Neoplasms by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Lung Neoplasms · Sanofi.

Enrollment
13th of 20
98 · median 132
Started
2006
with 1 other
Phase 2
7 of 23
none open now
Registered
6th of 23
by date

Among the 23 studies in Lung Neoplasms by Sanofi, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2006, is one of 7 in phase 2, and was the 6th registered.

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

1 of the 23 studies in Lung Neoplasms by Sanofi is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Lung Neoplasms by Sanofi, or all of them as a file.
02

Study summary

This study evaluated the efficacy and safety of aflibercept in the treatment of participants with advanced chemoresistant non-small cell lung adenocarcinoma (NSCLA).

Primary objective:

  • To determine the overall objective response rate (ORR) of AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®) 4.0 mg/kg intravenously (IV) every 2 weeks in participants with platinum- and erlotinib-resistant, locally advanced or metastatic NSCLA.

Secondary objective:

  • To assess duration of response (DR), progression-free survival (PFS), and overall survival (OS) in this participant population
  • To evaluate the safety profile of IV AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®).

This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation.

In addition, both Response Evaluation Criteria In Solid Tumors (RECIST) and Modified Response Evaluation Criteria In Solid Tumors (mRECIST) were used to assess tumors. Where as RECIST criteria only consider the longest diameter of the tumors for calculations pertaining to changes in tumor size, mRECIST assessments also account for the differences in the cavities of lesions observed in non-small-cell lung cancer (NSCLC). Responses based on RECIST and mRECIST are reported.

Read the detailed description

The study included :

  • A screening phase up to 21 days followed by registration
  • Treatment initiation within 5 working days of registration
  • A treatment phase with 14-day study treatment cycles until a study withdrawal criterion was met or up to the clinical database cut-off date (18 July 2008)
  • A follow-up phase - up to 60 days after end of treatment

Withdrawal criteria that led to treatment discontinuation were:

  • The participant or their legally authorized representative requested to withdraw
  • In the investigator's opinion, continuation of the study would be detrimental to the participant's well being, due to reasons such as disease progression, unacceptable toxicity, noncompliance, or logistical considerations.
  • A specific request by the Sponsor
  • Participant had intercurrent illness that prevented further administration of study treatment
  • Participant had more than 2 aflibercept dose reductions
  • Participant had arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset or worsening of pre-existing angina
  • Participant had radiographic evidence of intestinal obstruction (e.g., dilated loops of bowel accompanied by air-fluid levels) or gastrointestinal perforation (e.g., presence of extraluminal gas) requiring surgical intervention
  • Participant was lost to follow-up

After discontinuing treatment, participants remained on the study until the last post-treatment visit or until recovery of drug related toxicities, whichever was later.

03

Conditions studied

  • Pulmonary Diseases
  • Neoplasms, Lung

Keywords

  • lung
  • cancer
  • non-small-cell lung cancer
  • metastatic
  • carcinoma
  • lung neoplasm
  • lung diseases
  • angiogenesis
  • anti-angiogenesis
  • anti-angiogenesis inhibitors
  • cancer and other neoplasms
  • respiratory tract
  • (lung and bronchial) diseases
04

In context

Lung Neoplasms Reclassified

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

This study's enrollment of 98 is above the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Compared within Lung Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants who met the following criteria were eligible for the study.

Inclusion criteria

Inclusion Criteria:

  • confirmed non-small-cell lung adenocarcinoma that is locally advanced or
  • Prior treatment with at least 2 cancer drug regimens in the advanced disease setting
  • Platinum- and erlotinib-resistant disease defined by relapse or progression during or after treatment
  • by criteria
  • Performance status less than or equal to 2
  • Resolution of any toxic effects of prior therapy
  • Adequate organ and bone marrow function
  • Female patients must be , surgically sterile or using effective
  • Willing and able to comply with study procedures and sign

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of squamous-cell lung cancer or any second within the last 5 years (except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri)
  • Prior treatment with a VEGF or VEGF receptor inhibitor with the exception of bevacizumab (Avastin-TM)
  • Anticipation of a need for major surgical procedure
  • Treatment with chemotherapy, radiotherapy, surgery, blood products, or an agent within 3 weeks (6 weeks for nitrosoureas, mitomycin C, immunotherapy, or cytokine therapy) of study enrollment
  • Uncontrolled hypertension
  • Any severe or acute medical or psychiatric problem within the past 6 months requiring further investigation or that may cause undue risk for the patient's safety
  • History of , spinal cord compression, or carcinomatous meningitis, or new evidence of brain or
  • Active infection or on antiretroviral therapy for disease
  • Pregnant or breast-feeding

The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    aflibercept 4.0 mg/kg

    Participants with metastatic non-small-cell lung adenocarcinoma administered 4.0 mg/kg Aflibercept every 2 weeks until a study withdrawal criterion was met.

    Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Interventions

  • Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks. Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.

07

What researchers measure

Primary outcomes

  1. Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC).

    OR was either complete response (CR) or partial response (PR) based on RECIST or modified RECIST. CR was the disappearance of all target/nor-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD (According to modified RECIST, to calculate LD for cavitated lesions, the longest cavitation diameters were subtracted from the LD of cavitated target lesions). Assessments were made by the IRC, and confirmed by repeat tumor imaging 4-6 weeks after documentation of the initial response.

    Time frame: up to 2.5 years from initial treatment

  2. Confirmed Objective Response Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Investigator.

    OR was either complete response (CR) or partial response (PR) based on RECIST or modified RECIST. CR was the disappearance of all target/nor-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD (According to modified RECIST, to calculate LD for cavitated lesions, the longest cavitation diameters were subtracted from the LD of cavitated target lesions). Assessments were made by the Investigator, and confirmed by repeat tumor imaging 4-6 weeks after documentation of the initial response.

    Time frame: up to 2.5 years from initial treatment

Secondary outcomes

  1. Duration of Response (DR)

    DR was the time interval from the first complete response (CR) or partial response (PR) to the date of tumor progression or death from any cause, whichever was earlier. The duration of response was calculated only for those participants who achieved CR or PR.

    Time frame: up to 2.5 years from initial treatment

  2. Progression-free Survival (PFS) Time Assessed by the Independent Review Committee (IRC)

    PFS time was interval from the date of registration to the date of tumor progression (by RECIST or modified RECIST), or death from any cause, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. Progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors. If a participant did not progress or die, the date was censored to the date of last valid tumor assessment or the date of data cut-off, whichever was earlier.

    Time frame: up to 2.5 years from initial treatment

  3. Progression-free Survival (PFS) Time Assessed by the Investigator

    PFS time was interval from the date of registration to the date of tumor progression (by RECIST or modified RECIST), or death from any cause, whichever was earlier. If a participant did not progress or die, the date was censored to the date of last valid tumor assessment or the date of data cut-off, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. Progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors.

    Time frame: up to 2.5 years from initial treatment

  4. Overall Survival (OS)

    OS was the time interval between registration to the date of death from any cause. The median time for OS was estimated from Kaplan-Meier Plots. A participant was to be censored for the OS analysis if the participant was alive by the study cut-off date. The censoring date was either the date that the participant was last known to be alive or the date of study cut-off, whichever came earlier.

    Time frame: up to 2.5 years from initial treatment

  5. Heath-related Quality of Life (QOL) Measured Via the Lung Cancer Subscale

    HRQL was assessed with the Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS) questionnaire, which was completed by the participants on Day 1 of Cycle 1 only (for baseline value), then on Day 14 of each even-numbered cycle to evaluate the participants symptoms. The questionnaire scored 7 symptoms: shortness of breath, weight loss, clarity in thinking, coughing, appetite, chest tightness, ease of breathing, on a 0-4 scale. The total FACT-LCS score ranged from 0-28 (where 28 was related to the worst outcome). To calculate a change, the baseline score was subtracted from the score obtained after treatment. A negative value implied an improvement in HRQL.

    Time frame: Baseline to 2.5 years

  6. Overall Safety - Number of Participants With Adverse Events

    All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 60 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

    Time frame: up to 60+/-5 days after treatment discontinuation, or or until TEAE was resolved or stabilized (Collected till 18 July 2008)

  7. Number of Participants With Laboratory Abnormalities

    Participants with abnormal laboratory results for * Liver and renal function (Alkaline phosphatase, Alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], Creatinine, Hyperbilirubinemia), * Electrolytes (Hypercalcemia, Hypocalcemia, Hypokalemia, Hypernatremia, Hyponatremia, Hypophosphatemia) * Metabolism (Hypoalbuminemia, Hyperglycemia, Hypoglycemia) * Hematology (Partial thromboplastin time, Anemia, Lymphopenia, Neutropenia, Thrombocytopenia, Leukopenia)

    Time frame: Up to 2.5 years

  8. Peak of Free Aflibercept (VEGF Trap)

    Plasma free aflibercept levels after the first aflibercept infusion were estimated by a validated direct measured by enzyme-linked immunosorbent assay (ELISA), with a limit of quantification (LOQ) of 15.6 ng/mL.

    Time frame: Day 1 of the first infusion of Aflibercept (cycle 1)

  9. Free and VEGF-bound Trough Aflibercept Concentrations (VEGF Trap)

    Median free and VEGF-bound trough concentrations were determined at the end of each cycle beyond Cycle 2 (Steady-state) for each participant. Plasma free aflibercept levels were estimated by a validated direct ELISA, with an LOQ of 15.6 ng/mL. Plasma VEGF-bound aflibercept levels were also estimated by a separate validated direct ELISA with an LOQ of 43.9 ng/mL. Mean ± SD (coefficient of variation \[CV%\]) values were estimated from the median values calculated for each participant.

    Time frame: At the end of each treatment cycle (up to 2.5 years)

  10. Number of Participants With Anti-drug Antibodies

    Anti-drug antibodies in a participant's serum sample were assayed with an anti-drug ELISA assay, with a lower limit of quantitation of 238.4 ng/mL for an undiluted human serum sample. Serum for anti-drug antibody analysis was collected pre-dose on every fourth cycle after Cycle 1 Day 1 (at 8 week intervals), at end of treatment (EOT), and during post-treatment follow-up 60 days after the last dose.

    Time frame: up to 2.5 years after initial treatment

08

Results

Posted Dec 10, 2012

Participant flow

98 participants were registered into the study, of whom, 96 were exposed to study treatment.

Participant flow — Overall Study
MilestoneAflibercept 4.0 mg/kg
Started98
Treated96
Ongoing treatment2
Completed0
Not completed98
Withdrew: Disease progression / lack of efficacy51
Withdrew: Adverse event19
Withdrew: Participant's request9
Withdrew: Symptomatic / clinical progression11
Withdrew: Clinical deterioration / death2
Withdrew: General decline1
Withdrew: Pneumonia1
Withdrew: Did not take study medication2
Withdrew: Ongoing treatment2

Outcome measures

PrimaryConfirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC).

OR was either complete response (CR) or partial response (PR) based on RECIST or modified RECIST. CR was the disappearance of all target/nor-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD (According to modified RECIST, to calculate LD for cavitated lesions, the longest cavitation diameters were subtracted from the LD of cavitated target lesions). Assessments were made by the IRC, and confirmed by repeat tumor imaging 4-6 weeks after documentation of the initial response.

Time frame:
up to 2.5 years from initial treatment
Reported as:
Number · Participants
Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC).
ParticipantsAflibercept 4.0 mg/kg Arm Assessed by Modified RECISTAflibercept 4.0 mg/kg Arm Assessed by RECIST
Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC).00
SecondaryDuration of Response (DR)

DR was the time interval from the first complete response (CR) or partial response (PR) to the date of tumor progression or death from any cause, whichever was earlier. The duration of response was calculated only for those participants who achieved CR or PR.

Time frame:
up to 2.5 years from initial treatment

No measurements were reported for this outcome.

SecondaryProgression-free Survival (PFS) Time Assessed by the Independent Review Committee (IRC)

PFS time was interval from the date of registration to the date of tumor progression (by RECIST or modified RECIST), or death from any cause, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. Progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors. If a participant did not progress or die, the date was censored to the date of last valid tumor assessment or the date of data cut-off, whichever was earlier.

Time frame:
up to 2.5 years from initial treatment
Reported as:
Median · weeks
Progression-free Survival (PFS) Time Assessed by the Independent Review Committee (IRC)
weeksAflibercept 4.0 mg/kg Arm Assessed by Modified RECISTAflibercept 4.0 mg/kg Arm Assessed by RECIST
Progression-free Survival (PFS) Time Assessed by the Independent Review Committee (IRC)11.3 (9.3 to 16.1)11.3 (9.3 to 16.1)
SecondaryProgression-free Survival (PFS) Time Assessed by the Investigator

PFS time was interval from the date of registration to the date of tumor progression (by RECIST or modified RECIST), or death from any cause, whichever was earlier. If a participant did not progress or die, the date was censored to the date of last valid tumor assessment or the date of data cut-off, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. Progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors.

Time frame:
up to 2.5 years from initial treatment
Reported as:
Median · weeks
Progression-free Survival (PFS) Time Assessed by the Investigator
weeksAflibercept 4.0 mg/kg Arm Assessed by Modified RECISTAflibercept 4.0 mg/kg Arm Assessed by RECIST
Progression-free Survival (PFS) Time Assessed by the Investigator12.0 (10.0 to 16.0)11.9 (9.7 to 14.7)
SecondaryOverall Survival (OS)

OS was the time interval between registration to the date of death from any cause. The median time for OS was estimated from Kaplan-Meier Plots. A participant was to be censored for the OS analysis if the participant was alive by the study cut-off date. The censoring date was either the date that the participant was last known to be alive or the date of study cut-off, whichever came earlier.

Time frame:
up to 2.5 years from initial treatment
Reported as:
Median · months
Overall Survival (OS)
monthsAflibercept 4.0 mg/kg
Overall Survival (OS)26.9 (21.0 to 49.3)
SecondaryHeath-related Quality of Life (QOL) Measured Via the Lung Cancer Subscale

HRQL was assessed with the Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS) questionnaire, which was completed by the participants on Day 1 of Cycle 1 only (for baseline value), then on Day 14 of each even-numbered cycle to evaluate the participants symptoms. The questionnaire scored 7 symptoms: shortness of breath, weight loss, clarity in thinking, coughing, appetite, chest tightness, ease of breathing, on a 0-4 scale. The total FACT-LCS score ranged from 0-28 (where 28 was related to the worst outcome). To calculate a change, the baseline score was subtracted from the score obtained after treatment. A negative value implied an improvement in HRQL.

Time frame:
Baseline to 2.5 years
Reported as:
Mean · score on a scale
Heath-related Quality of Life (QOL) Measured Via the Lung Cancer Subscale
score on a scaleAflibercept 4.0 mg/kg
Baseline FACT-LCS Score (N=83)19.9 ± 3.9
Change from baseline at Cycle 2 (N=58)-1.5 ± 3.6
Change from baseline at Cycle 4 (N=41)-1.9 ± 4.7
Change from baseline at Cycle 6 (N=25)-1.0 ± 5.0
Change from baseline at Cycle 8 (N=13)-1.4 ± 4.7
Change from baseline at Cycle 10 (N=10)-1.7 ± 6.9
Change from baseline to last assessment (N=70)-3.3 ± 5.2
SecondaryOverall Safety - Number of Participants With Adverse Events

All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 60 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

Time frame:
up to 60+/-5 days after treatment discontinuation, or or until TEAE was resolved or stabilized (Collected till 18 July 2008)
Reported as:
Number · participants
Overall Safety - Number of Participants With Adverse Events
participantsAflibercept 4.0 mg/kg
With any TEAE96
With any Serious TEAE47
With any TEAE leading to Death16
with any TEAE leading to Treatment discontinuation19
SecondaryNumber of Participants With Laboratory Abnormalities

Participants with abnormal laboratory results for * Liver and renal function (Alkaline phosphatase, Alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], Creatinine, Hyperbilirubinemia), * Electrolytes (Hypercalcemia, Hypocalcemia, Hypokalemia, Hypernatremia, Hyponatremia, Hypophosphatemia) * Metabolism (Hypoalbuminemia, Hyperglycemia, Hypoglycemia) * Hematology (Partial thromboplastin time, Anemia, Lymphopenia, Neutropenia, Thrombocytopenia, Leukopenia)

Time frame:
Up to 2.5 years
Reported as:
Number · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsAflibercept 4.0 mg/kg
LIVER AND RENAL FUNCTION- Alkaline Phosphatase39
LIVER AND RENAL FUNCTION - ALT35
LIVER AND RENAL FUNCTION - AST37
LIVER AND RENAL FUNCTION - Creatinine15
LIVER AND RENAL FUNCTION - Hyperbilirubinemia4
ELECTROLYTES - Hypercalcemia6
ELECTROLYTES - Hypocalcemia15
ELECTROLYTES - Hyperkalemia24
ELECTROLYTES - Hypokalemia10
ELECTROLYTES - Hypernatremia5
ELECTROLYTES - Hyponatremia41
ELECTROLYTES - Hypophosphatemia (N=91)14
METABOLISM - Hypoalbuminemia (N=91)44
METABOLISM - Hyperglycemia81
METABOLISM - Hypoglycemia10
HEMATOLOGY - Partial thromboplastin time (N=81)30
HEMATOLOGY - Anemia34
HEMATOLOGY - Lymphopenia (N=84)60
HEMATOLOGY - Neutropenia (N=78)4
HEMATOLOGY - Thrombocytopenia11
HEMATOLOGY - Leukopenia11
SecondaryPeak of Free Aflibercept (VEGF Trap)

Plasma free aflibercept levels after the first aflibercept infusion were estimated by a validated direct measured by enzyme-linked immunosorbent assay (ELISA), with a limit of quantification (LOQ) of 15.6 ng/mL.

Time frame:
Day 1 of the first infusion of Aflibercept (cycle 1)
Reported as:
Mean · micrograms/mL
Peak of Free Aflibercept (VEGF Trap)
micrograms/mLAflibercept 4.0 mg/kg
Peak of Free Aflibercept (VEGF Trap)71.4 ± 31.8
SecondaryFree and VEGF-bound Trough Aflibercept Concentrations (VEGF Trap)

Median free and VEGF-bound trough concentrations were determined at the end of each cycle beyond Cycle 2 (Steady-state) for each participant. Plasma free aflibercept levels were estimated by a validated direct ELISA, with an LOQ of 15.6 ng/mL. Plasma VEGF-bound aflibercept levels were also estimated by a separate validated direct ELISA with an LOQ of 43.9 ng/mL. Mean ± SD (coefficient of variation \[CV%\]) values were estimated from the median values calculated for each participant.

Time frame:
At the end of each treatment cycle (up to 2.5 years)
Reported as:
Mean · micrograms/mL
Free and VEGF-bound Trough Aflibercept Concentrations (VEGF Trap)
micrograms/mLAflibercept 4.0 mg/kg
Trough free aflibercept concentration9.53 ± 6.28
Trough VEGF-bound aflibercept concentration3.48 ± 1.04
PrimaryConfirmed Objective Response Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Investigator.

OR was either complete response (CR) or partial response (PR) based on RECIST or modified RECIST. CR was the disappearance of all target/nor-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD (According to modified RECIST, to calculate LD for cavitated lesions, the longest cavitation diameters were subtracted from the LD of cavitated target lesions). Assessments were made by the Investigator, and confirmed by repeat tumor imaging 4-6 weeks after documentation of the initial response.

Time frame:
up to 2.5 years from initial treatment
Reported as:
Number · participants
Confirmed Objective Response Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Investigator.
participantsAflibercept 4.0 mg/kg Arm Assessed by Modified RECISTAflibercept 4.0 mg/kg Arm Assessed by RECIST
Objective response (OR)22
Complete response (CR)00
Partial response (PR)22
SecondaryNumber of Participants With Anti-drug Antibodies

Anti-drug antibodies in a participant's serum sample were assayed with an anti-drug ELISA assay, with a lower limit of quantitation of 238.4 ng/mL for an undiluted human serum sample. Serum for anti-drug antibody analysis was collected pre-dose on every fourth cycle after Cycle 1 Day 1 (at 8 week intervals), at end of treatment (EOT), and during post-treatment follow-up 60 days after the last dose.

Time frame:
up to 2.5 years after initial treatment
Reported as:
Number · participants
Number of Participants With Anti-drug Antibodies
participantsAflibercept 4.0 mg/kg
Number of Participants With Anti-drug Antibodies0

Adverse events

Collected over From treatment initiation to February 24, 2009.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
4 mg/kg—48/96 (50%)93/96 (96.9%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
Event4 mg/kg
DyspnoeaRespiratory, thoracic and mediastinal disorders8/96
Disease progressionGeneral disorders7/96
PneumoniaInfections and infestations6/96
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/96
Cardiac failure congestiveCardiac disorders2/96
FatigueGeneral disorders2/96
Non-cardiac chest painGeneral disorders2/96
SepsisInfections and infestations2/96
DehydrationMetabolism and nutrition disorders2/96
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/96
Most frequent other events
Showing 10 of 48
Most frequent other events
Event4 mg/kg
FatigueGeneral disorders39/96
HeadacheNervous system disorders38/96
HypertensionVascular disorders38/96
DyspnoeaRespiratory, thoracic and mediastinal disorders37/96
ConstipationGastrointestinal disorders27/96
DysphoniaRespiratory, thoracic and mediastinal disorders27/96
AnorexiaMetabolism and nutrition disorders24/96
NauseaGastrointestinal disorders23/96
CoughRespiratory, thoracic and mediastinal disorders22/96
Oedema peripheralGeneral disorders20/96

Baseline characteristics

Age Continuous
Age Continuous(years)Aflibercept 4.0 mg/kg
Mean60.2 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 4.0 mg/kg
Female58
Male40
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Aflibercept 4.0 mg/kg
Caucasian79
Black3
Asian, Oriental5
Unknown or Not Reported11
09

Study locations

3 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Paris, France
10

References and documents

Publications

  • Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol. 2010 Jul;5(7):1054-9. doi: 10.1097/jto.0b013e3181e2f7fb. PubMed 20593550 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 4 years 5 months after primary completion. A results delay was requested in Jul 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2006
First posted
Jan 31, 2006
Start
Jan 2006
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results delay requested
Jul 21, 2011
Results first posted
Dec 10, 2012
Last update
Dec 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00284141
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 31, 2006
Start date
Jan 2006
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Dec 10, 2012
Last update
Dec 10, 2012

Study contacts

ICD CSD
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion